What is Regenerative Medicine?
Regenerative medicine aims to replace tissues and organs that were broken by diseases, trauma and congenital issues contrary to the current clinical practices that mainly focus on treating symptoms with medicines and invasive surgery. Regenerative medicinal treatment uses tools like tissue culture engineering and cellular therapies in combination with artificial organs and medical devices to achieve regeneration of cells and tissues. This combined approach can enhance the natural healing process where it is most needed and replace the functions of the organs that were permanently damaged. The treatment is based on the theory that our bodies heal on their own when they suffer minor cuts and ailments and have the power to regenerate cells. Regenerative medicine aims to harness that power and use it for healing and importantly accelerate the process by means of clinical ways. RHEO™ with its components activates the processes using innovative clinical procedures and achieves the desired results.
RHEO™ Activates Local Microenvironment
Components of RHEO™ together works to create a favorable environment where the healing process can take place naturally. They create a Local Microenvironment Activation® or LMA®.at the injury site and activate Endothelial cells, Pericytes, and Mesenchymal Stromal cells (MSCs) which support the microenvironment by achieving a series of growth steps and regulating local immune responses. The above elements are responsible for controlling characteristics such as stromal support cells, gap junctions, soluble factors, extracellular matrix proteins, blood vessels, and neural inputs.
Human Amniotic Tissue
The amniotic membrane (AM) tissue is a source for a particular interest and it is readily available and obtained multi-potent stem cells and factors that encourage tissue healing. Human placenta is the most popular source of this tissue supply for regenerative therapy. Popularity of the amniotic membrane is related to readily available tissues that are discarded at birth. The amniotic tissues harvested from human placenta naturally contain healthy extracellular matrix that will help provide the scaffolding and support that the healing area needs vitally. These are the reasons why amniotic tissues are considered and adapted as the ideal biomaterial in the use of surgical procedures.
We Achieve Life Changes
At Texas Medical & Wellness Clinic in Victoria, Our mission is to develop procedures that change lives and RHEO™ is a life changing procedure of allograft that has changed the lives of thousands who have been suffering from ailment same as yours. Our goal has achieved these positive outcomes without a single adverse side effect or event.
Our human tissue allograft procedures are governed and controlled by strict quality management standards which are in compliance with the Food and Drug Administration (FDA) and the American Association of Tissue Banks® (AATB).
Frequently Asked Questions about RHEO™
Q. is RHEO™ safe?
A: Yes, we have framed and implemented strict guidelines on donor eligibility, transmittable disease screening, tissue handling, and reduction in bio-burden and end-to-end traceability of procedures. Products involved in the procedure are quarantined till third party screening is complete and ready for release and donor’s eligibility is established after the final approval of our Medical Director.
Q: How long does the procedure take?
A: it depends on the area being treated. The procedure normally will take a single visit to complete. The required the treatment plan specific to your disease will be explained by your doctor.
Q: Does the procedure hurt?
A: Not much, because the procedure of Allograft is non-surgical and for short duration thus produces less pain
Q: How soon will I see results?
A: recovery time will vary with factors like extent of tissue damage and overall physical health. Your physician will provide you with more details on this subject after the procedure.
RHEO™ is a perinatal tissue-derived allograft. It is designated as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) by the U.S. Food and Drug Administration (FDA), minimally manipulated, and produced in accordance with the FDA regulations for Good Tissue Practices (21 CFR 1270, 1271) in our AATB® accredited lab.